Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease

19 juni 2026 bijgewerkt door: Xiaomu Li, First Affiliated Hospital of Zhejiang University

Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in adults with type 2 diabetes mellitus and chronic kidney disease (eGFR >= 30 mL/min/1.73 m^2 and UACR 30-2000 mg/g) who are already receiving a maximum tolerated dose of an ACE inhibitor or ARB. A total of 148 participants are randomized 1:1, stratified by baseline UACR (<300 vs >=300 mg/g), to oral finerenone (10 or 20 mg once daily, titrated by serum potassium and eGFR) or matching placebo, on top of standard background therapy, for 180 days, followed by a 30-day off-treatment follow-up. Albuminuria regression is defined as both an improvement in Kidney Disease: Improving Global Outcomes albuminuria category, from A3 to A2 or A1, or from A2 to A1, and a more than 30% reduction in urinary albumin-to-creatinine ratio from baseline. The outcome will be reported as the percentage of participants meeting this definition at Day 180.

Studie Overzicht

Gedetailleerde beschrijving

Background and rationale: Finerenone is an oral, highly selective nonsteroidal mineralocorticoid receptor antagonist approved in China for the treatment of chronic kidney disease associated with type 2 diabetes (with albuminuria). In the phase III FIDELIO-DKD and FIGARO-DKD trials, finerenone added to a maximum tolerated dose of a renin-angiotensin system inhibitor significantly and durably reduced the urine albumin-to-creatinine ratio (UACR) and lowered the risk of kidney and cardiovascular events, with a manageable hyperkalemia risk. A meaningful reduction in albuminuria is an established early surrogate for slowing CKD progression and reducing cardiovascular risk. This study evaluates whether finerenone can achieve early regression of albuminuria in patients with type 2 diabetes and CKD.

Design: This is a multicenter, randomized, double-blind, placebo-controlled trial conducted at up to 12 sites in China. A planned 148 participants are allocated 1:1 to finerenone or matching placebo using central, block randomization (interactive response technology), stratified by baseline UACR (<300 vs >=300 mg/g). Participants and investigators are blinded; placebo tablets are identical in appearance to finerenone, and intervention-period UACR samples are assayed centrally after study completion to preserve blinding.

Population: Eligible participants are adults with type 2 diabetes and CKD (eGFR >= 30 mL/min/1.73 m^2 and UACR 30-2000 mg/g) who have received a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days and have serum potassium <= 5.0 mmol/L.

Intervention and dose titration: The starting dose is determined by screening eGFR: 10 mg once daily for 30 <= eGFR < 60 mL/min/1.73 m^2, or 20 mg once daily for eGFR >= 60 mL/min/1.73 m^2. The dose is up-titrated to 20 mg, maintained, interrupted, or down-titrated to 10 mg based on serum potassium and eGFR at scheduled and, if needed, unscheduled safety visits. Treatment continues for 180 days.

Visit schedule: a screening period (Day -30 to -1; V1); a treatment period ; and an off-treatment follow-up at Day 210 +/- 5 (V7). Unscheduled safety visits and early-discontinuation visits are performed as needed.

Endpoints: The primary endpoint is the albuminuria regression rate at 180 days, defined as a reduction in UACR KDIGO albuminuria category (A3 to A2 or A1, or A2 to A1) together with a >=30% reduction in UACR from baseline. Secondary endpoints include the change in UACR, the rate of regression to normoalbuminuria, the proportions achieving >=30/40/50% UACR reduction, KDIGO GFR-Albuminuria category improvement, the change in UACR 30 days after discontinuation, the change in eGFR slope, and the change in blood pressure. Safety endpoints include adverse events, serious adverse events, and adverse events of special interest (notably serum potassium changes and hyperkalemia). Exploratory endpoints also included.

Studietype

Ingrijpend

Inschrijving (Geschat)

148

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China
        • The First Affiliated Hospital of Chongqing Medical University
        • Contact:
          • Zhihong Wang
          • Telefoonnummer: +8613883021919
    • Fujian
      • Fuzhou, Fujian, China
        • Fujian Provincial Hospital
        • Contact:
          • Junping Wen
          • Telefoonnummer: +8613559925729
    • Guangdong
      • Foshan, Guangdong, China
        • Sanshui Hospital, Zhujiang Hospital, Southern Medical University
        • Contact:
          • Zhen Zhang
          • Telefoonnummer: +8615913162742
      • Guangzhou, Guangdong, China
        • Nanfang Hospital, Southern Medical University
        • Contact:
          • Junyu Xue
          • Telefoonnummer: +8618613166333
    • Jiangsu
      • Nantong, Jiangsu, China
        • Nantong First People's Hospital
        • Contact:
          • Xueqin Wang
          • Telefoonnummer: +8613813609566
      • Suqian, Jiangsu, China
        • The First People's Hospital of Suqian
        • Contact:
          • Hong Zhu
          • Telefoonnummer: +8618012186759
      • Suzhou, Jiangsu, China
        • Suzhou Science and Technology City Hospital
        • Contact:
          • Zhimin Ma
          • Telefoonnummer: +8617715187073
    • Shaanxi
      • Xi'an, Shaanxi, China
        • Xi'an Daxing Hospital
        • Contact:
          • Ying Xing
          • Telefoonnummer: +8613991955717
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Zhongshan hospital, Fudan university
        • Contact:
          • Yuejuan Liu
          • Telefoonnummer: +8613472844268
      • Shanghai, Shanghai Municipality, China
        • Shanghai Municipal Hospital of Traditional Chinese Medicine
        • Contact:
          • Feng Tao
          • Telefoonnummer: +8613818808324
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310003
        • The First Affiliated Hospital, Zhejiang University School of Medicine
        • Contact:
      • Ningbo, Zhejiang, China
        • The First Affiliated Hospital of Ningbo University
        • Contact:
          • Li Li
          • Telefoonnummer: +8613757426626
      • Wenzhou, Zhejiang, China
        • The First Affiliated Hospital of Wenzhou Medical University
        • Contact:
          • Hong Zhu
          • Telefoonnummer: +8613758712421

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • 1. Age >= 18 years at the time of signing informed consent, male or female.
  • 2. Type 2 diabetes mellitus.
  • 3. Chronic kidney disease meeting BOTH of the following: eGFR (CKD-EPI) >= 30 mL/min/1.73 m^2, and UACR 30-2000 mg/g (mean of 3 measurements).
  • 4. Serum potassium <= 5.0 mmol/L.
  • 5. On a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days.
  • 6. Treatment with an SGLT-2 inhibitor, GLP-1 receptor agonist, or other agents affecting UACR is permitted, but the type and dose must be stable for at least 30 days before screening.

Exclusion Criteria:

  • 1. Type 1 diabetes, other specific types of diabetes, or gestational diabetes.
  • 2. HbA1c >= 8.0%.
  • 3. On renal replacement therapy.
  • 4. Acute kidney injury within 180 days before the screening visit.
  • 5. Hepatic impairment (Child-Pugh class C).
  • 6. Blood pressure > 160/100 mmHg, or systolic blood pressure < 90 mmHg, at the screening visit.
  • 7. Bilateral renal artery stenosis.
  • 8. Known hypersensitivity to the study drug (active substance or excipients).
  • 9. Treatment with finerenone within 60 days before screening.
  • 10. Stroke, transient ischemic attack, acute coronary syndrome (myocardial infarction, CABG, PCI), or hospitalization for worsening heart failure within 90 days before the screening visit.
  • 11. NYHA class II-IV heart failure.
  • 12. Addison's disease.
  • 13. Gastrointestinal surgery that may affect drug absorption.
  • 14. Any other history, condition, therapy, or uncontrolled concomitant disease that makes the participant unsuitable for the study or unlikely to complete it (e.g., active malignancy or other disease with life expectancy < 12 months).
  • 15. Treatment with a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin, nefazodone), a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, phenobarbital, St. John's wort), or a moderate CYP3A4 inducer (e.g., efavirenz) that cannot be discontinued for at least 7 days before randomization.
  • 16. Treatment with another mineralocorticoid receptor antagonist (e.g., spironolactone, eplerenone, esaxerenone) or a potassium-sparing diuretic (e.g., amiloride, triamterene) that cannot be discontinued for at least 60 days before the screening visit.
  • 17. Biopsy-confirmed non-diabetic kidney disease (e.g., IgA nephropathy).
  • 18. Immunosuppressive therapy, or glucocorticoid use by any route other than topical or inhaled, within the past 180 days.
  • 19. Participation in another interventional clinical study or use of any investigational product within 90 days before randomization.
  • 20. History of alcohol or drug abuse.
  • 21. Women of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using adequate contraception during the study.
  • 22. Any other condition deemed by the investigator to make the participant unsuitable for the study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Finerenone
Finerenone film-coated tablets, orally once daily, on top of standard background therapy. Starting dose determined by screening eGFR: 10 mg if 30 <= eGFR < 60 mL/min/1.73 m^2, or 20 mg if eGFR >= 60 mL/min/1.73 m^2. Dose up-titrated to 20 mg, maintained, interrupted, or down-titrated to 10 mg based on serum potassium and eGFR. Treatment duration 180 days.
Oral finerenone 10 mg or 20 mg once daily, with dose titration by serum potassium and eGFR, for 180 days.
Placebo-vergelijker: Placebo
Matching placebo tablets identical in appearance to finerenone, orally once daily, on top of standard background therapy, following the same dosing and titration schedule. Treatment duration 180 days.
Matching placebo tablets, identical in appearance to finerenone, orally once daily, following the same dosing and titration schedule, for 180 days.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Albuminuria regression rate
Tijdsspanne: 180 days
Proportion of participants achieving albuminuria regression, defined as a reduction in UACR KDIGO albuminuria category (A3 to A2 or A1, or A2 to A1) together with a >=30% reduction in UACR from baseline.
180 days

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio
Tijdsspanne: Baseline and 180 days
Urinary albumin-to-creatinine ratio will be measured in mg/g. Percent change from baseline will be calculated as: (Day 180 UACR - baseline UACR) / baseline UACR × 100%.
Baseline and 180 days
Percentage of Participants With Normoalbuminuria
Tijdsspanne: 180 days
Normoalbuminuria is defined as urinary albumin-to-creatinine ratio less than 30 mg/g at Day 180.
180 days
Percentage of Participants by UACR Reduction Response Category at Day 180
Tijdsspanne: Baseline to Day 180
Percent reduction in urinary albumin-to-creatinine ratio (UACR) from baseline to Day 180 will be calculated for each participant. Participants will be classified into one of four mutually exclusive UACR reduction response categories: no more than 30% reduction, more than 30% to no more than 40% reduction, more than 40% to no more than 50% reduction, and more than 50% reduction. Participants with no reduction or an increase in UACR will be included in the no more than 30% reduction category. The outcome will be reported as the percentage of participants in each response category.
Baseline to Day 180
Percentage of Participants With Improvement in Kidney Disease: Improving Global Outcomes Albuminuria Category at Day 180
Tijdsspanne: Baseline to Day 180
Improvement in albuminuria category is defined as a change from A3 to A2 or A1, or from A2 to A1, according to Kidney Disease: Improving Global Outcomes urinary albumin-to-creatinine ratio categories.
Baseline to Day 180
Change From Day 180 to Day 210 in Urinary Albumin-to-Creatinine Ratio
Tijdsspanne: Day 180 to Day 210
Change in urinary albumin-to-creatinine ratio from Day 180 to Day 210 will be assessed in mg/g, corresponding to the 30-day off-treatment follow-up period.
Day 180 to Day 210
Estimated Glomerular Filtration Rate Slope Through Day 180
Tijdsspanne: Baseline through Day 180
Estimated glomerular filtration rate will be calculated using the CKD-EPI equation. The eGFR slope through Day 180 will be estimated from serial eGFR measurements and reported in mL/min/1.73 m2 per year.
Baseline through Day 180
Change From Baseline in Systolic Blood Pressure at Day 180
Tijdsspanne: Baseline to Day 180
Change in systolic blood pressure from baseline to Day 180 will be assessed in mmHg.
Baseline to Day 180
Change From Baseline in Diastolic Blood Pressure at Day 180
Tijdsspanne: Baseline to Day 180
Change in diastolic blood pressure from baseline to Day 180 will be assessed in mmHg.
Baseline to Day 180

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants With Adverse Events
Tijdsspanne: From first dose through Day 210
The outcome will be reported as the percentage of participants experiencing at least one adverse event from first dose through the end of the 30-day off-treatment follow-up period.
From first dose through Day 210
Percentage of Participants With Serious Adverse Events
Tijdsspanne: From first dose through Day 210
The outcome will be reported as the percentage of participants experiencing at least one serious adverse event from first dose through the end of the 30-day off-treatment follow-up period.
From first dose through Day 210
Adverse events of special interest (AESI)
Tijdsspanne: Up to 210 days
Including change in serum potassium and incidence of hyperkalemia, incidence of eGFR decline >30% at Day 30, reversibility of eGFR after discontinuation, acute kidney injury, urogenital infection, severe hypoglycemia, symptomatic hypotension, and ketoacidosis
Up to 210 days
Change in Composite MRI-PDFF-derived Peri-organ Visceral Fat Fraction
Tijdsspanne: Baseline and 180 days
Abdominal magnetic resonance imaging proton density fat fraction will be used to quantify visceral fat fraction (%) in prespecified perirenal, peripancreatic, and perihepatic regions of interest. A composite peri-organ visceral fat fraction will be calculated for each participant as the arithmetic mean of the region-specific MRI-PDFF values from the perirenal, peripancreatic, and perihepatic regions. The outcome will be reported as the percentage-point change in the composite peri-organ visceral fat fraction from baseline to Day 180.
Baseline and 180 days
Change in Urine Metabolomic Composite Score
Tijdsspanne: Baseline to Day 180
Urine metabolomic features will be measured using a prespecified metabolomics platform. Normalized metabolite feature intensities will be standardized, and a urine metabolomic composite score will be calculated according to the statistical analysis plan. The outcome will be reported as change in composite score from baseline to Day 180.
Baseline to Day 180

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 juli 2026

Primaire voltooiing (Geschat)

31 oktober 2027

Studie voltooiing (Geschat)

31 december 2027

Studieregistratiedata

Eerst ingediend

14 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

19 juni 2026

Eerst geplaatst (Werkelijk)

25 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 juni 2026

Laatste update ingediend die voldeed aan QC-criteria

19 juni 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data will not be shared publicly.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren